Loading
AP
Aveo Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BAILEY MICHAEL P, was filed 03 Sept 2021.
Aveo Pharmaceuticals, Inc.: what insiders have been doing
Aveo Pharmaceuticals, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Aveo Pharmaceuticals, Inc. has had no insider filing for more than a year; the last one goes back to 19 January 2023.
Over the whole record (from 2017), the tally stands at 262 purchases and 3 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
279
Thresholds
n/a
Buy Volume
€162M
262 ops. · all time
Sell Volume
€2M
3 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$36.4M
Net income-US$45.9M-126.1% margin
Last declaration on 19 January 2023
Declarations279 total
375 shares@ US$15.00100.0% of flowCommon StockSEC:0000899243-23-002195:0
333,167 shares@ US$15.0095.1% of flowCommon StockSEC:0000899243-23-002183:0
41,841 shares@ US$15.00100.0% of flowCommon StockSEC:0000899243-23-002193:0
16,345 shares@ US$15.0094.7% of flowCommon StockSEC:0000899243-23-002191:0
26,499 shares@ US$6.203.2% of flowCommon StockSEC:0001628280-22-032490:0
3,952,957 shares0Common StockSEC:0001209191-22-054289:0
3,952,957 shares0Common StockSEC:0001209191-22-054290:0
3,952,957 shares0Common StockSEC:0001209191-22-054291:0
3,952,957 shares0Common StockSEC:0001209191-22-054287:0
3,952,957 shares0Common StockSEC:0001209191-22-054288:0
3,952,957 shares0Common StockSEC:0001209191-22-054286:0
3,952,957 shares0Common StockSEC:0001209191-22-054292:0
3,952,957 shares0Common StockSEC:0001209191-22-054281:0
15,000 shares@ US$6.481.7% of flowCommon StockSEC:0000899243-21-035140:0
Canonical exit: 30 Nov 2021 (T+90)
2,608 shares@ US$5.755.3% of flowCommon StockSEC:0000899243-21-032613:0
Canonical exit: 8 Nov 2021 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038234:0
Canonical exit: 17 Sept 2020 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038246:0
Canonical exit: 17 Sept 2020 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038244:0
Canonical exit: 17 Sept 2020 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038240:0
Canonical exit: 17 Sept 2020 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038243:0
Canonical exit: 17 Sept 2020 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038235:0
Canonical exit: 17 Sept 2020 (T+90)
1,428,571 shares@ US$5.25100.0% of flowCommon StockSEC:0001209191-20-038238:0
Canonical exit: 17 Sept 2020 (T+90)
150,000 shares@ US$0.59731.6% of flowCommon StockSEC:0000899243-19-028068:0
Canonical exit: 19 Feb 2020 (T+90)
4,347,827 shares@ US$1.1439.7% of flowCommon StockSEC:0001209191-19-023995:0
Canonical exit: 7 Jul 2019 (T+90)
4,347,827 shares@ US$1.1423.2% of flowCommon StockSEC:0001209191-19-023998:0
Canonical exit: 7 Jul 2019 (T+90)
25 of 279 declarations
About Aveo Pharmaceuticals, Inc.
AVEO PHARMACEUTICALS, INC. is a U.S.-based biopharmaceutical company listed on the NASDAQ in the United States, with a core focus on oncology. Founded in 2001 as GenPath Pharmaceuticals and renamed AVEO Pharmaceuticals in 2005, the company built its strategy around targeted cancer therapies aimed at diseases with significant unmet medical need. Its operating base has long been centered in the Cambridge/Boston, Massachusetts life-sciences cluster, which is consistent with its identity as a development-stage and commercial-stage oncology company. Following its integration into LG Chem’s corporate umbrella, AVEO is now described as an LG Chem company while retaining a distinct oncology franchise and product-development profile.
The company’s main business line is the commercialization and life-cycle management of FOTIVDA® (tivozanib), its lead marketed asset. FOTIVDA is an oral, selective VEGF receptor inhibitor approved in the United States for adult patients with relapsed or refractory advanced renal cell carcinoma after at least two prior systemic therapies. This makes AVEO a relatively concentrated oncology biotech with meaningful operating leverage if penetration of the drug improves, if prescribing expands, or if additional evidence supports broader clinical adoption. From a competitive standpoint, AVEO operates in a highly competitive oncology market dominated by large pharmaceutical groups and better-capitalized biotech peers. Its differentiation therefore depends on tivozanib’s selectivity profile, accumulated clinical data, commercial execution, and the ability to generate supporting evidence.
Read moreShow less
Beyond its marketed product, AVEO maintains a development pipeline that includes ficlatuzumab and AV-380/rilogrotug, signaling that the company is still pursuing pipeline optionality rather than relying solely on one asset. Geographically, AVEO remains primarily U.S.-focused, although tivozanib has had an international history and the company benefits from global scientific and corporate links through LG Chem. Recent milestones include the July 2024 announcement that the phase 3 TiNivo-2 study did not meet its primary endpoint, while the company continued presenting tivozanib data at major oncology congresses such as ASCO and ASCO GU in 2025. In January 2026, AVEO announced first patient dosing in a phase 1b/2 AML combination study of ficlatuzumab, underscoring its effort to broaden the pipeline. For French-speaking investors, AVEO is best viewed as a U.S. NASDAQ-listed oncology specialist with a narrow commercial base, a U.S.-centric footprint, and continuing clinical development optionality.
